794 related articles for article (PubMed ID: 28646699)
1. Insulin and the polycystic ovary syndrome.
Macut D; Bjekić-Macut J; Rahelić D; Doknić M
Diabetes Res Clin Pract; 2017 Aug; 130():163-170. PubMed ID: 28646699
[TBL] [Abstract][Full Text] [Related]
2. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Franks S
Clin Endocrinol (Oxf); 2011 Feb; 74(2):148-51. PubMed ID: 21121941
[TBL] [Abstract][Full Text] [Related]
3. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
[TBL] [Abstract][Full Text] [Related]
4. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ
Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and metabolic characteristics in polycystic ovary syndrome.
Glintborg D
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
[TBL] [Abstract][Full Text] [Related]
6. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.
Sam S; Ehrmann DA
Diabetologia; 2017 Sep; 60(9):1656-1661. PubMed ID: 28770330
[TBL] [Abstract][Full Text] [Related]
7. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
[TBL] [Abstract][Full Text] [Related]
8. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
9. Treatment of polycystic ovary syndrome with insulin-lowering agents.
Glueck CJ; Streicher P; Wang P
Expert Opin Pharmacother; 2002 Aug; 3(8):1177-89. PubMed ID: 12150695
[TBL] [Abstract][Full Text] [Related]
10. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Svendsen PF; Nilas L; Nørgaard K; Madsbad S
Ugeskr Laeger; 2005 Aug; 167(34):3147-51. PubMed ID: 16117910
[TBL] [Abstract][Full Text] [Related]
11. The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence.
Leeman L; Acharya U
J Obstet Gynaecol; 2009 Aug; 29(6):467-72. PubMed ID: 19697191
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance and the long-term consequences of polycystic ovary syndrome.
Bhathena RK
J Obstet Gynaecol; 2011; 31(2):105-10. PubMed ID: 21281021
[TBL] [Abstract][Full Text] [Related]
14. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
15. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance, polycystic ovary syndrome and metformin.
Pugeat M; Ducluzeau PH
Drugs; 1999; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
[TBL] [Abstract][Full Text] [Related]
17. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
18. Metformin in polycystic ovary syndrome.
Diamanti-Kandarakis E; Economou F; Palimeri S; Christakou C
Ann N Y Acad Sci; 2010 Sep; 1205():192-8. PubMed ID: 20840272
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
Anastasiou OE; Canbay A; Fuhrer D; Reger-Tan S
Arch Gynecol Obstet; 2017 Aug; 296(2):363-371. PubMed ID: 28608050
[TBL] [Abstract][Full Text] [Related]
20. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
